Pfizer Pharma GmbH, Linkstraße 10, 10785 Berlin, Germany.
Xcenda GmbH, Lange Laube 31, 30159 Hannover, Germany.
Vaccine. 2021 Jun 2;39(24):3287-3295. doi: 10.1016/j.vaccine.2021.04.029. Epub 2021 May 5.
In August 2015, the German Standing Committee on Vaccination (STIKO) changed the pneumococcal conjugate vaccination (PCV) schedule for mature infants from a 3+1 scheme to a 2+1 scheme. It was expected that a reduction of doses would be associated with a higher acceptance of the vaccination. Aim of this study was to assess vaccination rates and adherence for PCV after the change of recommendation based on real-world data.
A retrospective claims data analysis using the InGef Research Database was conducted. The study population consisted of all mature infants born in 2013 (last birth cohort completely under 3+1 recommendation) or 2016 (first birth cohort completely under 2+1 recommendation) with an individual follow-up of 24 months. Hexavalent combination vaccination (HEXA) with a consistent 3+1 recommendation was analyzed as reference.
After follow-up of 24 months, 90.9% (91.2%) of the 2016 (2013) cohort received at least one dose of PCV. At the same age, 67.7% of the 2013 cohort received a booster dose according to the 3+1 schedule and 75.6% of the 2016 cohort received a booster dose presumably either according to the 2+1 (71.7%) or 3+1 (3.9%) schedule. Of those receiving the booster dose, only 46.3% (2016) and 45.1% (2013) received the booster dose on time as recommended. The HEXA vaccination rate increased from 88.9% (2013) to 91.6% (2016) with a full series completion in 69.1% (2013) vs 72.9% (2016). The proportion of infants receiving the booster vaccination on time rose to 50.0% in 2016 (47.8% in 2013).
Although the rate for the PCV booster dose slightly increased, nearly a quarter of the infants born in 2016 did not receive a booster dose at all. Furthermore, vaccinations were still frequently delayed, and the rate of unvaccinated infants remained constant.
2015 年 8 月，德国疫苗接种常设委员会（STIKO）将成熟婴儿的肺炎球菌结合疫苗（PCV）接种计划从 3+1 方案改为 2+1 方案。预计减少剂量将与更高的疫苗接种接受率相关。本研究的目的是基于真实世界的数据评估推荐变更后 PCV 的接种率和接种依从性。
使用 InGef 研究数据库进行回顾性索赔数据分析。研究人群包括 2013 年（最后一个完全在 3+1 推荐下的出生队列）或 2016 年（第一个完全在 2+1 推荐下的出生队列）出生的所有成熟婴儿，个体随访时间为 24 个月。使用一致的 3+1 推荐的六价结合疫苗（HEXA）作为参考进行分析。
在 24 个月的随访后，2016 年（2013 年）队列的 90.9%（91.2%）至少接受了一剂 PCV。在相同的年龄，2013 年队列的 67.7%根据 3+1 方案接受了加强剂量，2016 年队列的 75.6%根据 2+1（71.7%）或 3+1（3.9%）方案接受了加强剂量。在接受加强剂量的人群中，只有 46.3%（2016 年）和 45.1%（2013 年）按照建议按时接受了加强剂量。HEXA 疫苗接种率从 2013 年的 88.9%增加到 2016 年的 91.6%，完全系列完成率从 2013 年的 69.1%增加到 2016 年的 72.9%。按时接受加强接种的婴儿比例从 2013 年的 50.0%上升到 2016 年的 50.0%（2016 年的 47.8%）。
尽管 PCV 加强剂量的接种率略有上升，但仍有近四分之一的 2016 年出生婴儿根本没有接种加强剂量。此外，疫苗接种仍经常延迟，未接种疫苗的婴儿比例保持不变。
